SCHEMBL16933668

SCHEMBL16933668

CNC(=O)c1ccc(-c2ccc(C(C)(C)NC(=O)N3CCN4CCC3CC4)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 3/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36
▸ NPY2R P49146 1/20 0.36
▸ HTR3A P46098 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.35
▸ SCD O00767 1/20 0.35
▸ SCD5 Q86SK9 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MKNK1 Q9BUB5 1/20 0.34
▸ MKNK2 Q9HBH9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16933438 0.90 HPGD (0.47) CHRNA7HTR3AHRH3
SCHEMBL16933621 0.87 EPHX2 (0.38) CHRNA7EPHX2NR1H4NPY2R
SCHEMBL16933605 0.83 MLYCD (0.43) EPHX2HRH3ALDH1A1KMT2A
SCHEMBL16933694 0.81 CHRNA7 (0.40) CHRNA7HRH3MEN1KMT2A
SCHEMBL16933550 0.80 CHRNA7 (0.39) CHRNA7HRH3ALDH1A1
SCHEMBL16933882 0.79 HRH3 (0.35) CHRNA7HTR3AHRH3
SCHEMBL16933454 0.78 HRH3 (0.45) HRH3ALDH1A1KMT2A
SCHEMBL16933688 0.77 MMP2 (0.41) CHRNA7HTR3AHRH3
SCHEMBL16006983 0.76 CHRNA3 (0.38) HTR3AMEN1ALDH1A1KMT2ANPSR1
SCHEMBL29386743 0.76 NTMT1 (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 — — US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885EPHX2 1284/4885NR1H4 2275/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885EPHX2 1284/4885NR1H4 2275/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA CHRNA7 4652/4885EPHX2 1326/4885NR1H4 2391/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC CHRNA7 4254/4885EPHX2 1943/4885NR1H4 3220/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885EPHX2 1284/4885NR1H4 2275/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885EPHX2 1284/4885NR1H4 2275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback